New combo therapy aims to stop leukemia return after transplant
NCT ID NCT07493408
First seen Mar 29, 2026 · Last updated Apr 30, 2026 · Updated 5 times
Summary
This study tests whether adding the drug asciminib to standard therapy can prevent leukemia from coming back after a stem cell transplant. It includes 45 adults with Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia or blastic phase chronic myeloid leukemia. Participants take asciminib plus a tyrosine kinase inhibitor or the inhibitor alone, and are monitored for relapse and side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BLASTIC TRANSFORMATION OF CHRONIC MYELOID LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Hong Kong
Hong Kong, Hong Kong
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.